
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29049340</article-id><article-id pub-id-type="pmc">5648228</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0186709</article-id><article-id pub-id-type="publisher-id">PONE-D-17-30890</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Histology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Histology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject><subj-group><subject>Cancer Chemotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject><subj-group><subject>Chemotherapy</subject><subj-group><subject>Cancer Chemotherapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Oncology</subject><subj-group><subject>Cancer Chemotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Clinical Oncology</subject><subj-group><subject>Cancer Chemotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Carcinomas</subject><subj-group><subject>Adenocarcinomas</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject><subj-group><subject>Chemotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Materials Science</subject><subj-group><subject>Materials by Structure</subject><subj-group><subject>Mixtures</subject><subj-group><subject>Aerosols</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Ascites</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma</article-title><alt-title alt-title-type="running-head">PIPAC for pancreatic peritoneal metastasis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khosrawipour</surname><given-names>Tanja</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Khosrawipour</surname><given-names>Veria</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="author-notes" rid="currentaff001"><sup>&#x000a4;</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1915-4694</contrib-id><name><surname>Giger-Pabst</surname><given-names>Urs</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of General Surgery &#x00026; Therapy Center for Peritoneal carcinomatosis, St. Mary&#x02019;s Hospital Herne, Ruhr University Bochum, Bochum, Germany</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Basic Research Laboratories of the Department of Surgery, St. Mary&#x02019;s Hospital Herne, Ruhr-University Bochum, Bochum, Germany</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ma</surname><given-names>Wen-Lung</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>China Medical University, TAIWAN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="current-aff" id="currentaff001"><label>&#x000a4;</label><p>Current address: Department of Orthopedic and Trauma Surgery, Ortho-Klinik Dortmund, Dortmund, Germany</p></fn><corresp id="cor001">* E-mail: <email>urs.pabst@elisabethgruppe.de</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>10</issue><elocation-id>e0186709</elocation-id><history><date date-type="received"><day>22</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>5</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Khosrawipour et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Khosrawipour et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0186709.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma were treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC), initial clinical findings are presented.</p></sec><sec id="sec002"><title>Methods</title><p>Single institution, tertiary referral center certified for therapy of peritoneal disease. Prospective data collection of PIPAC therapy with doxorubicin 1.5 mg/m<sup>2</sup> and cisplatin 7.5 mg/m<sup>2</sup> of body surface delivered at intervals of six weeks. The outcome criteria were microscopic pathological response, survival and adverse events (v4.0 CTCAE).</p></sec><sec id="sec003"><title>Results</title><p>A total of 20 patients (m/f = 3:1) with a mean age of 64.9 (range: 45.0 to 87.0) years underwent 41 PIPAC procedures without intraoperative complications. The mean number of PIPAC cycles was 2.1 (range: one to four). Ten patients with &#x02265; 2 PIPAC applications were eligible for histological analysis to assess carcinoma regression. Complete or high grade tumor regression was found in two (10%) and five (25%) patients, respectively. An overall median survival of 36.6 weeks after the first PIPAC application was observed. One patient died postoperatively due to small bowel obstruction. No CTCAE level 3 and 4 complications occurred.</p></sec><sec id="sec004"><title>Conclusion</title><p>In about one third of patients, repeated PIPAC therapy did induce histological regression of systemic chemo-resistant PC of pancreatic adenocarcinoma. Prospective randomized trials are needed to further clarify any clinical impact of such observations.</p></sec></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>The reported incidence of pancreatic adenocarcinoma (PAC) in western countries is increasing. With approximately 49,000 new cases diagnosed and 41,000 observed deaths in 2015 in the USA, this tumor entity has become the fourth and fifth leading cause of death in men and women, respectively [<xref rid="pone.0186709.ref001" ref-type="bibr">1</xref>]. While surgical resection remains the only possible curative option, local non-resectability and/or synchronous metastasis reduce eligibility of patients that undergo curative resection to less than 15% [<xref rid="pone.0186709.ref002" ref-type="bibr">2</xref>]. However, even after complete surgical resection, 80% of patients will suffer from postoperative tumor recurrence within the first two years following surgery [<xref rid="pone.0186709.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0186709.ref005" ref-type="bibr">5</xref>]. A frequent site of recurrence is the peritoneum, as 40% to 50% of cases show peritoneal metastasis [<xref rid="pone.0186709.ref006" ref-type="bibr">6</xref>]. At present, palliative systemic chemotherapy is considered the treatment of choice for peritoneal metastasized patients. However, the prognosis remains poor, as the reported median overall survival is reported to be around eight months [<xref rid="pone.0186709.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0186709.ref008" ref-type="bibr">8</xref>].</p><p>It is evident that treatment options in such patients are still scarce and measures should be taken to develop more effective treatment strategies [<xref rid="pone.0186709.ref009" ref-type="bibr">9</xref>]. Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC) is a novel therapeutic method to treat patients suffering from advanced PC. Ex-vivo, in animal as well as data obtained in human patients suggest a higher local drug biodisponibility, an optimized intra-abdominal drug distribution pattern and a better therapeutic index compared to antecedent data reported for liquid IPC [<xref rid="pone.0186709.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pone.0186709.ref012" ref-type="bibr">12</xref>]. Currently, PIPAC is not well documented in the medical literature to treat PC of PAC. We report our experience with PIPAC in such patients.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Patients and regulatory framework</title><p>Since April 2012, our institution (University Hospital of the Ruhr-University Bochum) is a certified referral center for the treatment of peritoneal carcinomatosis by the German Society for General and Visceral Surgery. Encouraging safety and feasibility data obtained from tumor entities of non-pancreatic origin prompted us to offer PIPAC therapy to patients suffering from PC of pancreatic origin. Prior to PIPAC therapy, each patient was evaluated at our multidisciplinary tumor board. The indication for PIPAC therapy was decided on a case-by-case individual basis. Only patients with histologically documented and progressive PC after or under evidence-based systemic chemotherapy or patients who did not qualify for systemic chemotherapy due to medical contraindications underwent PIPAC therapy. Although there were no strict exclusion criteria for PIPAC therapy, patients suffering from clinical signs of gastro-intestinal occlusion and/or a Karnofsky Index (KI) &#x0003c; 50% were excluded. We intended to deliver at least three PIPAC cycles separated by a six week time interval. The study was performed in line with the guidelines of the Declaration of Helsinki, and each patient was asked to give written informed consent for data collection as well as for publication of data in an anonymous manner. Data collection and analysis were performed with the approval of the local Institutional Review Board (Ethics Committee of the Ruhr University Bochum, Germany; Registry Number 15&#x02013;5280)</p></sec><sec id="sec008"><title>PIPAC procedure</title><p>The PIPAC procedure has previously been described in detail by our group [<xref rid="pone.0186709.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0186709.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0186709.ref014" ref-type="bibr">14</xref>]. The access to the abdominal cavity was usually obtained via a mini laparotomy just lateral to the left rectus muscle in the midclavicular line at the level of the umbilicus. Peritoneal biopsies from all four abdominal quadrants (if possible) were retrieved and consecutively prepared for histological analysis. A blunt 12 mm trocar was introduced and a constant capnoperitoneum of 12 mmHg established. A second trocar of 5 mm diameter was then placed under video-optic guidance. When present, ascites was completely removed and the amount documented. Then, a full inspection of the abdominal cavity was performed and the extent of PC (according to the Sugarbaker&#x02019;s peritoneal carcinomatosis index) documented. Peritoneal biopsies from all four abdominal quadrants (if possible) as well as a local peritonectomy specimen of 3.0 x 3.0 cm in size were retrieved and consecutively prepared for histological analysis. For an optimum of intraperitoneal drug aerosol distribution, the PIPAC-Micropump (MIP<sup>&#x000ae;</sup> Micropump/Capnopen (Reger Medizintechnik, Rottweil, Germany)) was inserted into the 12mm trocar with a maximum spraying distance between the MIP<sup>&#x000ae;</sup> nozzle orifice and the small bowel [<xref rid="pone.0186709.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0186709.ref016" ref-type="bibr">16</xref>]. Doxorubicin at a dose of 1.5 mg/m<sup>2</sup> body surface in a 50 ml NaCl 0.9% followed by Cisplatin at a dose of 7.5 mg/m<sup>2</sup> in a 150 ml NaCl 0.9% were aerosolized and consecutively applied. The therapeutic aerosol was maintained at 12 mmHg for 30 min at 37 C. Finally, the aerosol was evacuated from the abdominal cavity using a Closed Aerosol Waste System, trocars were then retracted and laparoscopy ended. Previous reported safety standards for PIPAC therapy were followed [<xref rid="pone.0186709.ref017" ref-type="bibr">17</xref>].</p></sec><sec id="sec009"><title>Data collection follow-up and statistical analysis</title><p>Data were collected by clinical study nurses according to a prospective data base including electronic archiving and video recording of the PIPAC procedures. Follow-up data was obtained by telephone calls (UGP) until 1<sup>st</sup> July 2017 or until death occurred. Histological tumor response was assessed by an independent pathological reference center. To evaluate the histological tumor regression grade (TRG) associated with PIPAC therapy, the following criteria were applied: TRG I: &#x0003c; 10% to no tumor cells destroyed; TRG II a: 10% to 50% of tumor cells destroyed; TRG II b: 51% to 90% of tumor cells destroyed; TRG III: &#x0003e; 90% of tumor cells destroyed and TRG IV: no viable tumor cells with acellular pools of mucin [<xref rid="pone.0186709.ref018" ref-type="bibr">18</xref>]. In this study, whenever different scores were found in different tissue samples of the same patient, the lowest TRG value observed was reported. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (v4.0 CTCAE) [<xref rid="pone.0186709.ref019" ref-type="bibr">19</xref>]. Data analysis was conducted retrospectively. Overall survival was modelled in a Kaplan-Meier curve with IMB<sup>&#x000ae;</sup> SPSS<sup>&#x000ae;</sup> Statistics 24.</p></sec></sec><sec sec-type="results" id="sec010"><title>Results</title><p>Between June 2015 and June 2017, a total of 20 patients (m:f = 3:1) with a mean age of 64.9 years (range: 45 to 87) and a median Karnofsky Index of 80% (IQR: 70% to 90%) underwent a total of 41 consecutive PIPAC applications. Eight patients had undergone previous curative pancreatic resection but developed histologically confirmed metachronous PC. In another twelve patients, diagnostic laparoscopy/laparotomy confirmed synchronous PC. All patients had progressive PC under or after a minimum of one line of systemic chemotherapy or systemic treatment had to be stopped due to severe systemic side effects. The median time interval between the diagnosis of pancreatic adenocarcinoma and the first PIPAC application was 331 (IQR: 170.5 to 472.5) days. Patient demographic data as well as details on previous surgical procedures and systemic chemotherapy are summarized in <xref ref-type="table" rid="pone.0186709.t001">Table 1</xref>.</p><table-wrap id="pone.0186709.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0186709.t001</object-id><label>Table 1</label><caption><title>Patient demographic and details on previous surgical interventions and systemic chemotherapy treatment before PIPAC.</title></caption><alternatives><graphic id="pone.0186709.t001g" xlink:href="pone.0186709.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Pat.N&#x000b0;</th><th align="center" rowspan="1" colspan="1">Age (yrs)</th><th align="center" rowspan="1" colspan="1">Sex</th><th align="center" rowspan="1" colspan="1">Date of diagnosis of PAC (mm/yy)</th><th align="center" rowspan="1" colspan="1">Type and date of previous surgery (mm/yy)</th><th align="center" rowspan="1" colspan="1">Details about previous systemic chemotherapy treatments</th><th align="center" rowspan="1" colspan="1">ECOG prior to PIPAC N&#x000b0; 1</th><th align="center" rowspan="1" colspan="1">Days between diagnosis of PAC &#x00026; 1. PIPAC</th><th align="center" rowspan="1" colspan="1">Comments</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>1</bold></td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">f</td><td align="center" rowspan="1" colspan="1">08/14</td><td align="center" rowspan="1" colspan="1">Pancreatic tail resection 12/14</td><td align="center" rowspan="1" colspan="1">7 x Gemcitabine and nab-Paclitaxel</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">Progress under systemic therapy; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>2</bold></td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">01/14</td><td align="center" rowspan="1" colspan="1">DL 01/14</td><td align="center" rowspan="1" colspan="1">12 x Gemcitabine and nab-Paclitaxel</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">465</td><td align="center" rowspan="1" colspan="1">Progress after systemic therapy; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>3</bold></td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">f</td><td align="center" rowspan="1" colspan="1">05/14</td><td align="center" rowspan="1" colspan="1">WR 05/15</td><td align="center" rowspan="1" colspan="1">12 x FOLFIRINOX, 5 x Gemcitabine Gemcitabine &#x00026; Erlotinib</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">510</td><td align="center" rowspan="1" colspan="1">Progress under second-line systemic therapy; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>4</bold></td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">12/15</td><td align="center" rowspan="1" colspan="1">DL 12/15</td><td align="center" rowspan="1" colspan="1">8 x Gemcitabine</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">Progress under systemic therapy; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>5</bold></td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">03/15</td><td align="center" rowspan="1" colspan="1">Pancreatic tail resection &#x00026; splenectomy 04/15</td><td align="center" rowspan="1" colspan="1">5 x FOLFIRINOX Gemcitabine &#x00026; nab-Paclitaxel</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">360</td><td align="center" rowspan="1" colspan="1">Gemcitabine &#x00026; nab-Paclitaxel and PIPAC</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>6</bold></td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">03/15</td><td align="center" rowspan="1" colspan="1">DL 03/15</td><td align="center" rowspan="1" colspan="1">8 x FOLFIRINOX</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">480</td><td align="center" rowspan="1" colspan="1">Progress after systemic therapy; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>7</bold></td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">10/14</td><td align="center" rowspan="1" colspan="1">DL 10/14</td><td align="center" rowspan="1" colspan="1">7 x FOLFIRINOX</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">Progress under systemic therapy; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>8</bold></td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">f</td><td align="center" rowspan="1" colspan="1">12/14</td><td align="center" rowspan="1" colspan="1">WR 01/15</td><td align="center" rowspan="1" colspan="1">4 x Gemcitabine</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">270</td><td align="center" rowspan="1" colspan="1">Stop of systemic therapy due to neutropenia; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>9</bold></td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">f</td><td align="center" rowspan="1" colspan="1">03/14</td><td align="center" rowspan="1" colspan="1">WR 03/15</td><td align="center" rowspan="1" colspan="1">1 x FOLFIRINOX 6 x Gemcitabine</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">480</td><td align="center" rowspan="1" colspan="1">Stop FOLFIRINOX due to side effects; progress under Gemcitabine; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>10</bold></td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">02/15</td><td align="center" rowspan="1" colspan="1">DL 02/15</td><td align="center" rowspan="1" colspan="1">3 x FOLFIRINOX</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">210</td><td align="center" rowspan="1" colspan="1">Stop Folfirinox due to side effects; Patient refused any systemic therapy; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>11</bold></td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">04/15</td><td align="center" rowspan="1" colspan="1">Thoracoscopy and Wedge resection 04/15 DL 07/16</td><td align="center" rowspan="1" colspan="1">2 x Gemcitabine &#x00026; nab-Paclitaxel 6 x FOLFIRINOX</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">455</td><td align="center" rowspan="1" colspan="1">Synchronous lung metastasis; PIPAC and FOLFIRINOX (80%) combined</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>12</bold></td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">02/13</td><td align="center" rowspan="1" colspan="1">WR 02/13</td><td align="center" rowspan="1" colspan="1">Gemcitabine mono12 x FOLFIRINOX 4 x Gemcitabine &#x00026; nab-Paclitaxel</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1290</td><td align="center" rowspan="1" colspan="1">PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>13</bold></td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">11/15</td><td align="center" rowspan="1" colspan="1">DL 11/15</td><td align="center" rowspan="1" colspan="1">Gemcitabine mono</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">Progressive disease under systemic therapy; kidney insufficiency; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>14</bold></td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">f</td><td align="center" rowspan="1" colspan="1">6/16</td><td align="center" rowspan="1" colspan="1">DL 10/16</td><td align="center" rowspan="1" colspan="1">6 x Gemcitabine &#x00026; nab-Paclitaxel 3 x FOLFIRINOX</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">191</td><td align="center" rowspan="1" colspan="1">Folfirinox and PIPAC</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>15</bold></td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">05/16</td><td align="center" rowspan="1" colspan="1">DL 05/16</td><td align="center" rowspan="1" colspan="1">22 x Gemcitabine &#x00026; nab-Paclitaxel</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">350</td><td align="center" rowspan="1" colspan="1">Stop systemic chemotherapy due to progressive disease; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>16</bold></td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">01/17</td><td align="center" rowspan="1" colspan="1">DL 01/17</td><td align="center" rowspan="1" colspan="1">5 x Gemcitabine &#x00026; nab-Paclitaxel 2 x FLOX</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">Duodenal stent placement prior to PIPAC;; pulmonary metastasis under Gemcitabine &#x00026; nab-Paclitaxel; Stop FLOX due to severe side effects PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>17</bold></td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">03/13</td><td align="center" rowspan="1" colspan="1">DL 03/13</td><td align="center" rowspan="1" colspan="1">10 x FOLFIRINOX, 10 x Gemcitabine &#x00026; nab-Paclitaxel, 5 x Cisplatin &#x00026; Gemcitabine</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1439</td><td align="center" rowspan="1" colspan="1">Progressive disease; kidney insufficiency; PIPAC mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>18</bold></td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">06/16</td><td align="center" rowspan="1" colspan="1">Pancreatic tail resection &#x00026; splenectomy 06/16</td><td align="center" rowspan="1" colspan="1">1 x FOLFIRINOX 6 x Gemcitabine &#x00026; nab-Paclitaxel</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">312</td><td align="center" rowspan="1" colspan="1">Gemcitabine &#x00026; nab Paclitaxel &#x00026; PIPAC</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>19</bold></td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">04/16</td><td align="center" rowspan="1" colspan="1">Explorative laparotomy 04/16</td><td align="center" rowspan="1" colspan="1">22 x Gemcitabine &#x00026; nab-Paclitaxel; Gemcitabine mono</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">423</td><td align="center" rowspan="1" colspan="1">Synchronous PC and liver metastasis; PIPAC and Gemcitabine mono</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>20</bold></td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">m</td><td align="center" rowspan="1" colspan="1">06/14</td><td align="center" rowspan="1" colspan="1">WR 06/14</td><td align="center" rowspan="1" colspan="1">6 x Gemcitabine mono</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">299</td><td align="center" rowspan="1" colspan="1">PC and synchronous lung metastasis; PIPAC and Gemcitabine mono</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>yrs = years; m = male; f = female; PAC = pancreatic adenocarcinoma; WR = Whipple resection; DL = diagnostic laparoscopy; KI = Karnofsky Index</p></fn></table-wrap-foot></table-wrap><p>With an initial mean PCI score of 26.6 (range: 1 to 39) and malignant ascites of 1403 ml (range: 0 to 7000), all patients received a minimum of one PIPAC application. In three patients, safe access to the abdominal cavity for a second PIPAC application failed due to severe adhesions&#x02014;representing a secondary non-access rate of 3/41 (7.3%) procedures. The mean number of PIPAC applications was 2.1 (range: one to four) whereas four patients received four applications, three patients three, three patients two and ten patients only one. The mean procedure time was 93.0 (range: 75 to 125) minutes with no observed intraoperative complications. Mild postoperative abdominal discomfort and pain (CTCAE grade 1) was recorded for 14/41 (34%) procedures. Profuse nausea and vomiting (CTCAE grade 2) was observed in one case (2.4%). No CTCAE grade 3 and 4 complications occurred. Although not in direct correlation with the PIPAC procedure itself, one patient died eleven days after the first PIPAC application (CTCAE grade 5) due to small bowel obstruction which represents a procedure related mortality rate (1/41) of 2.4%.</p><p>Out of twenty patients, ten patients received &#x02265; 2 PIPAC cycles and were therefore eligible for histological tumor regression grade (TRG) analysis. In two patients (10%), all biopsies as well as in the local parietal peritonectomy specimen, complete tumor regression (TRG grade 4) was observed. Furthermore, high grade tumor regression (TRG 3) was documented in five patients (25%). No histological response to PIPAC therapy was observed in three (15%) patients (TRG grade 1). Taken together, any objective histological tumor regression was observed in 7/20 (35%) patients.</p><p>The reasons for premature interruption of PIPAC therapy (minimum of three cycles) were rapid physical deterioration with clinical and/or radiological signs of subileus/ileus, severe tumor cachexia syndrome or exitus letalis in eight patients (40%) as well as secondary non-access in three other patients (15%). On an intention-to-treat analysis, one third of patients could be managed with at least three PIPAC therapies, two patients are awaiting for their third PIPAC cycle. The median survival after the first PIPAC cycle was 36.6 weeks (95% CI: 36.6&#x02013;51.1 weeks). After a median follow up of 43.6 weeks (95% CI: 8.5&#x02013;78.6 weeks), eleven patients have died. Details about PIPAC therapy, perioperative complications, and histological regression are summarized in <xref ref-type="table" rid="pone.0186709.t002">Table 2</xref>. Survival data after the first PIPAC cycle are given in <xref ref-type="fig" rid="pone.0186709.g001">Fig 1</xref>.</p><fig id="pone.0186709.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0186709.g001</object-id><label>Fig 1</label><caption><title>Overall survival curve Kaplan-Meier after first PIPAC application.</title></caption><graphic xlink:href="pone.0186709.g001"/></fig><table-wrap id="pone.0186709.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0186709.t002</object-id><label>Table 2</label><caption><title>Perioperative details about PIPAC therapy.</title></caption><alternatives><graphic id="pone.0186709.t002g" xlink:href="pone.0186709.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1"><break/>Pat. N&#x000b0;</th><th align="center" colspan="4" rowspan="1">PIPAC N&#x000b0; 1</th><th align="center" colspan="4" rowspan="1">PIPAC N&#x000b0; 2</th><th align="center" colspan="4" rowspan="1">PIPAC N&#x000b0; 3</th><th align="center" colspan="4" rowspan="1">PIPAC N&#x000b0; 4</th><th align="left" rowspan="2" colspan="1">Comments:</th></tr><tr><th align="center" rowspan="1" colspan="1">PCI Score</th><th align="center" rowspan="1" colspan="1">Ascites (ml)</th><th align="center" rowspan="1" colspan="1">CTCAE 1&#x02013;5</th><th align="center" rowspan="1" colspan="1">TRG 1&#x02013;4</th><th align="center" rowspan="1" colspan="1">PCI Score</th><th align="center" rowspan="1" colspan="1">Ascites (ml)</th><th align="center" rowspan="1" colspan="1">CTCAE 1&#x02013;5</th><th align="center" rowspan="1" colspan="1">TRG 1&#x02013;4</th><th align="center" rowspan="1" colspan="1">PCI Score</th><th align="center" rowspan="1" colspan="1">Ascites (ml)</th><th align="center" rowspan="1" colspan="1">CTCAE 1&#x02013;5</th><th align="center" rowspan="1" colspan="1">TRG 1&#x02013;4</th><th align="center" rowspan="1" colspan="1">PCI Score</th><th align="center" rowspan="1" colspan="1">Ascites (ml)</th><th align="center" rowspan="1" colspan="1">CTCAE 1&#x02013;5</th><th align="center" rowspan="1" colspan="1">TRG 1&#x02013;4</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Exitus letalis 08/15 before PIPAC N&#x000b0; 4</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>2</bold></td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">3000</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Exitus letalis 06/15 eleven days after PIPAC N&#x000b0; 1 due to postoperative ileus</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>3</bold></td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">***</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Exitus letalis 08/16</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>4</bold></td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3000</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Rapid clinical deterioration after PIPAC N&#x000b0; 1; Exitus letalis 02/16</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>5</bold></td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Secondary non-access after PIPAC N&#x000b0; 1 due to adhesions; Exitus letalis 11/16</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>6</bold></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Alive 06/17 with no chemotherapy</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>7</bold></td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">4500</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Exitus letalis 06/16; rapid clinical deterioration after PIPAC N&#x000b0; 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>8</bold></td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Clinical deterioration after PIPAC N&#x000b0; 3; Exitus letalis 03/16</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>9</bold></td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Secondary non-access due to adhesions; Exitus letalis 09/15</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>10</bold></td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">3500</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">5600</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Exitus letalis 02/16; Stop PIPAC due to clinical deterioration</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>11</bold></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Alive 06/17 but clinical deterioration</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>12</bold></td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Alive 06/17; no treatment;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>13</bold></td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">7000</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Stop PIPAC due to clinical deterioration; Exitus letalis 01/17</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>14</bold></td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Exitus letalis 05/17 due to sepsis</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>15</bold></td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Alive 06/17; stop PIPAC due to subileus</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>16</bold></td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">1500</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Alive 06/17</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>17</bold></td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">3500</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">stop PIPAC due to rapid disease progress; Exitus letalis 04/17</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>18</bold></td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">1000</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Secondary-non access due to adhesions;<break/>alive 06/17</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>19</bold></td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">500</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">700</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Third PIPAC scheduled; alive 06/17</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>20</bold></td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Exitus letalis 09/16</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>TRG 1&#x02013;4 = tumor regression grade (1 = 10% to no tumor cells destroyed; 2 = 10% to 50% of tumor cells destroyed; 3 = 90% of tumor cells; 4 = no viable tumor cells and acellular pool of mucin); PCI = Sugarbaker&#x02019;s peritoneal carcinomatosis index; N/A = not applicable; CTCEA = Common Terminology Criteria of Adverse Events (v4.0); Pat. N&#x000b0; = patient number</p></fn><fn id="t002fn002"><p>*** = PCI not determinable due to diffuse sclerosis of peritoneum</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions" id="sec011"><title>Discussion</title><p>Systemic chemotherapy has poor efficacy and often severe toxic side effects, questioning its clinical use [<xref rid="pone.0186709.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0186709.ref020" ref-type="bibr">20</xref>]. Inadequate drug delivery to solid tumors is a major cause of treatment failure. Following systemic administration, the drug delivery to the cancer cells in solid tumors involves transport within a vessel, transport across the vascular wall into surrounding tissue and transport through the intestinal space within the tumor. These processes are determined by the physiochemical properties of the drugs and the biological properties of the tumor. Among the peritoneal tumors, drug delivery to pancreatic cancer is problematic, owing to the high stromal fraction (&#x0003e; 80%) resulting in a high interstitial pressure and in the sparse vascular that is only partially functional and physically separated from cancer cells [<xref rid="pone.0186709.ref021" ref-type="bibr">21</xref>].</p><p>Based on such data, intraperitoneal chemotherapy (IPC) represents a logical alternative route for delivering high drug concentrations to tumors located in the peritoneal cavity. A combination of liquid IPC and intravenous chemotherapy for the treatment of systemic gemcitabine refractory PC of PAC has already been tested. A median overall survival of 4.8 months and a high number of CTCEA grade 3 and 4 adverse events such as neutropenia (34.0%), anemia (31.0%), and catheter-related infections (9.0%) have been reported [<xref rid="pone.0186709.ref022" ref-type="bibr">22</xref>]. Even with such a combined and more aggressive therapy, a high number of severe toxic side effects are observed and the overall survival remains poor.</p><p>Although the pharmacokinetics of PIPAC and liquid IPC have never been directly compared and there is a lack of evidence about the optimum drug dose, duration between therapy intervals, pressure of the capnoperitoneum, and exposure time for PIPAC therapy, PIPAC has rapidly gained wide acceptance in the daily management of patients suffering from PC of gastro-intestinal and gynecological origin.</p><p>Published data on safety and feasibility from our PIPAC program, as well as data published from other independent groups mainly based on one phase II study for recurrent PC of ovarian cancer and several retrospective case series of peritoneal metastatic gastric or colo-rectal origin, report a high feasibility and safety profile of PIPAC therapy. In this current series, aside from one patient suffering from profuse nausea and vomiting requiring prolonged intravenous fluid resuscitation and anti-emetic therapy (CTCAE grade 2), adverse events were self-limiting abdominal discomfort and perioperative nausea (CTCAE grade 1). No systemic side effects such as deterioration of kidney and/or liver function or myelosuppression were observed. Although one patient died after the first PIPAC cycle from small bowel obstruction due to progressive disease, the safety and feasibility data of PIPAC therapy observed in this current study are in line with previous reports on PIPAC therapy for PC of other origin than pancreatic cancer [<xref rid="pone.0186709.ref023" ref-type="bibr">23</xref>].</p><p>A key element of PIPAC is repetitive diagnostic staging laparoscopy which allows quantification of PC by visual inspection (PCI score) and objective histological therapy response by multiple biopsies. However, staging laparoscopy is known to underestimate the extent of PC, especially in patients with adhesions due to previous surgery such as 40% in this series. In our experience, another limiting factor for correct PCI documentation is the formation of varying but also extensive degrees of diffuse peritoneal sclerosis after repetitive PIPAC applications. This phenomenon has already been described after liquid intraperitoneal instillation for a variety of different cytostatic drugs [<xref rid="pone.0186709.ref024" ref-type="bibr">24</xref>]. Therefore, the PCI score is an invalid tool to monitor any therapy response of repetitive PIPAC applications.</p><p>However, patients who had a minimum of two PIPAC cycles were accessible for histological analysis of the tumor response. An objective tumor regression was observed in 35% of patients. Nevertheless, previous studies with patients suffering from end-stage PC of gastric or colo-rectal cancer reported a higher number of objective histological regressions in 50% to 70% of cases [<xref rid="pone.0186709.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0186709.ref014" ref-type="bibr">14</xref>].</p><p>In a very recently published small pilot study by Graversen et al., histological regression of first-line systemic chemotherapy resistant PC of pancreatic adenocarcinoma after PIPAC application was observed in 75% of patients [<xref rid="pone.0186709.ref025" ref-type="bibr">25</xref>]. However, these data must be interpreted with caution. First, it is a small pilot study dealing with only five patients. Second, their systemic first-line chemotherapy is not the standard in a western patient population. Finally, histological tumor regression was assessed with a new and until now never used or clinically validated peritoneal carcinomatosis regressions grading score [<xref rid="pone.0186709.ref026" ref-type="bibr">26</xref>]. Nevertheless, the data of Graversen et al. are important since these data are the first of its kind which report about an activity of PIPAC on systemic chemo-resistant PC of pancreatic origin and furthermore support our findings.</p><p>We are aware, that our current data needs to be interpreted with caution. First, this study is retrospective with only a small number of patients included. Second, patients with a rapid disease progression and deterioration of their general condition were not referred to our clinic for possible PIPAC therapy. Therefore, a certain selection bias to physically fitter patients treated with PIPAC must be assumed.</p><p>Currently it remains unclear whether histological regression due to PIPAC does have any clinical impact. Nevertheless, such data observed in end-stage PC patients are encouraging. In a phase II study combining intravenous and intraperitoneal liquid chemotherapy in gemcitabine refractory PC of PAC, Takahara et al. reported about a median overall survival of 4.8 months but with a high number of severe toxic side effects [<xref rid="pone.0186709.ref022" ref-type="bibr">22</xref>]. This contrasts with our current study with a median survival of nine months observed after the first PIPAC cycle and with almost no severe complications. Existing data on a combination therapy with systemic chemotherapy and PIPAC are furthermore promising. PIPAC was found not to further enhance severe toxic side effects already observed for systemic chemotherapy [<xref rid="pone.0186709.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0186709.ref027" ref-type="bibr">27</xref>]. Such a combination approach could be a further step towards improving the clinical outcome without increasing the risk of more severe side effects.</p></sec><sec sec-type="conclusions" id="sec012"><title>Conclusion</title><p>PIPAC therapy in patients suffering from end-stage PC or pancreatic adenocarcinoma is feasible and safe as reported in earlier studies on ovarian and other gastro-intestinal tumor entities. However, the number of patients with an observed objective histological tumor regression in this study is inferior compared to that reported for PC of gastric or colo-rectal cancer treated with PIPAC. Further studies are needed to clarify if PIPAC has a possible positive impact on the clinical outcome of such patients.</p></sec></body><back><ack><p>We are thankful to Mrs. J. Kosel (research assistant), Mrs. J. Koke and K. Voitz (study nurses) for data collection. Special thanks to B. S. Schultheis, MD, for drafting and critical revision and important intellectual content of the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0186709.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name>, <name><surname>Miller</surname><given-names>KD</given-names></name>, <name><surname>Jemal</surname><given-names>A</given-names></name>. <article-title>Cancer statistics, 2015</article-title>. <source>CA Cancer J Clin</source>. <year>2015</year>
<season>Jan-Feb</season>;<volume>65</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>29</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3322/caac.21254">10.3322/caac.21254</ext-link>.</comment> Epub 2015 Jan 5. <pub-id pub-id-type="pmid">25559415</pub-id></mixed-citation></ref><ref id="pone.0186709.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Schneider</surname><given-names>G</given-names></name>, <name><surname>Siveke</surname><given-names>JT</given-names></name>, <name><surname>Eckel</surname><given-names>F</given-names></name>, <name><surname>Schmid</surname><given-names>RM</given-names></name>. <article-title>Pancreatic cancer: basic and clinical aspects</article-title>. <source>Gastroenterology</source>. <year>2005</year>
<month>5</month>;<volume>128</volume>(<issue>6</issue>):<fpage>1606</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="pmid">15887154</pub-id></mixed-citation></ref><ref id="pone.0186709.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Sohn</surname><given-names>TA</given-names></name>, <name><surname>Yeo</surname><given-names>CJ</given-names></name>, <name><surname>Cameron</surname><given-names>JL</given-names></name>, <name><surname>Koniaris</surname><given-names>L</given-names></name>, <name><surname>Kaushal</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators</article-title>. <source>J Gastrointest Surg</source>. <year>2000</year>
<season>Nov-Dec</season>;<volume>4</volume>(<issue>6</issue>):<fpage>567</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="pmid">11307091</pub-id></mixed-citation></ref><ref id="pone.0186709.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>T</given-names></name>, <name><surname>Yagi</surname><given-names>S</given-names></name>, <name><surname>Kinoshita</surname><given-names>H</given-names></name>, <name><surname>Sakamoto</surname><given-names>Y</given-names></name>, <name><surname>Okada</surname><given-names>K</given-names></name>, <name><surname>Uryuhara</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Long-term survival after resection of pancreatic cancer: A single-center retrospective analysis</article-title>. <source>World J Gastroenterol</source>. <year>2015</year>
<month>1</month>
<day>7</day>; <volume>21</volume>(<issue>1</issue>): <fpage>262</fpage>&#x02013;<lpage>268</lpage>. Published online 2015 Jan 7. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3748/wjg.v21.i1.262">10.3748/wjg.v21.i1.262</ext-link></comment>
<pub-id pub-id-type="pmid">25574100</pub-id></mixed-citation></ref><ref id="pone.0186709.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Smeenk</surname><given-names>HG</given-names></name>, <name><surname>Tran</surname><given-names>TC</given-names></name>, <name><surname>Erdmann</surname><given-names>J</given-names></name>, <name><surname>van Eijck</surname><given-names>CH</given-names></name>, <name><surname>Jeekel</surname><given-names>J</given-names></name>. <article-title>Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?</article-title>
<source>Langenbecks Arch Surg</source>. <year>2005</year>;<volume>390</volume>:<fpage>94</fpage>&#x02013;<lpage>103</lpage>. Review. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00423-004-0476-9">10.1007/s00423-004-0476-9</ext-link></comment>
<pub-id pub-id-type="pmid">15578211</pub-id></mixed-citation></ref><ref id="pone.0186709.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Warshaw</surname><given-names>AL</given-names></name>, <name><surname>Fern&#x000e1;ndez-del Castillo</surname><given-names>C</given-names></name>. <article-title>Pancreatic carcinoma</article-title>. <source>N Engl J Med</source>. <year>1992</year>
<month>2</month>
<day>13</day>;<volume>326</volume>(<issue>7</issue>):<fpage>455</fpage>&#x02013;<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM199202133260706">10.1056/NEJM199202133260706</ext-link></comment>
<pub-id pub-id-type="pmid">1732772</pub-id></mixed-citation></ref><ref id="pone.0186709.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Conroy</surname><given-names>T</given-names></name>, <name><surname>Desseigne</surname><given-names>F</given-names></name>, <name><surname>Ychou</surname><given-names>M</given-names></name>, <name><surname>Bouch&#x000e9;</surname><given-names>O</given-names></name>, <name><surname>Guimbaud</surname><given-names>R</given-names></name>, <name><surname>B&#x000e9;couarn</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>. <source>N Engl J Med</source>. <year>2011</year>
<month>5</month>
<day>12</day>;<volume>364</volume>(<issue>19</issue>):<fpage>1817</fpage>&#x02013;<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1011923">10.1056/NEJMoa1011923</ext-link></comment>
<pub-id pub-id-type="pmid">21561347</pub-id></mixed-citation></ref><ref id="pone.0186709.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Tabernero</surname><given-names>J</given-names></name>, <name><surname>Chiorean</surname><given-names>EG</given-names></name>, <name><surname>Infante</surname><given-names>JR</given-names></name>, <name><surname>Hingorani</surname><given-names>SR</given-names></name>, <name><surname>Ganju</surname><given-names>V</given-names></name>, <name><surname>Weekes</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer</article-title>. <source>Oncologist</source>. <year>2015</year>
<month>2</month>; <volume>20</volume>(<issue>2</issue>): <fpage>143</fpage>&#x02013;<lpage>150</lpage>. Published online 2015 Jan 12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1634/theoncologist.2014-0394">10.1634/theoncologist.2014-0394</ext-link></comment>
<pub-id pub-id-type="pmid">25582141</pub-id></mixed-citation></ref><ref id="pone.0186709.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Thomassen</surname><given-names>I</given-names></name>, <name><surname>Lemmens</surname><given-names>VE</given-names></name>, <name><surname>Nienhuijs</surname><given-names>SW</given-names></name>, <name><surname>Luyer</surname><given-names>MD</given-names></name>, <name><surname>Klaver</surname><given-names>YL</given-names></name>, <name><surname>de Hingh</surname><given-names>IH</given-names></name>. <article-title>Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study</article-title>. <source>Pancreas</source>. <year>2013</year>
<month>1</month>;<volume>42</volume>(<issue>1</issue>):<fpage>72</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MPA.0b013e31825abf8c">10.1097/MPA.0b013e31825abf8c</ext-link></comment>
<pub-id pub-id-type="pmid">22850624</pub-id></mixed-citation></ref><ref id="pone.0186709.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Sola&#x000df;</surname><given-names>W</given-names></name>, <name><surname>Hetzel</surname><given-names>A</given-names></name>, <name><surname>Nadiradze</surname><given-names>G</given-names></name>, <name><surname>Sagynaliev</surname><given-names>E</given-names></name>, <name><surname>Reymond</surname><given-names>MA</given-names></name>. <article-title>Description of a novel approach for intraperitoneal drug delivery and the related device</article-title>. <source>Surg Endosc</source>. <year>2012</year>
<month>7</month>;<volume>26</volume>(<issue>7</issue>):<fpage>1849</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00464-012-2148-0">10.1007/s00464-012-2148-0</ext-link>.</comment> Epub 2012 May 12. <pub-id pub-id-type="pmid">22580869</pub-id></mixed-citation></ref><ref id="pone.0186709.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Solass</surname><given-names>W</given-names></name>, <name><surname>Kerb</surname><given-names>R</given-names></name>, <name><surname>M&#x000fc;rdter</surname><given-names>T</given-names></name>, <name><surname>Giger-Pabst</surname><given-names>U</given-names></name>, <name><surname>Strumberg</surname><given-names>D</given-names></name>, <name><surname>Tempfer</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy</article-title>. <source>Ann Surg Oncol</source>. <year>2014</year>
<month>2</month>;<volume>21</volume>(<issue>2</issue>):<fpage>553</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1245/s10434-013-3213-1">10.1245/s10434-013-3213-1</ext-link>.</comment> Epub 2013 Sep 5. <pub-id pub-id-type="pmid">24006094</pub-id></mixed-citation></ref><ref id="pone.0186709.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Dedrick</surname><given-names>RL</given-names></name>, <name><surname>Flessner</surname><given-names>MF</given-names></name>. <article-title>Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure</article-title>. <source>J Natl Cancer Inst</source>. <year>1997</year>
<month>4</month>
<day>2</day>;<volume>89</volume>(<issue>7</issue>):<fpage>480</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="pmid">9086004</pub-id></mixed-citation></ref><ref id="pone.0186709.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Demtr&#x000f6;der</surname><given-names>C</given-names></name>, <name><surname>Solass</surname><given-names>W</given-names></name>, <name><surname>Zieren</surname><given-names>J</given-names></name>, <name><surname>Strumberg</surname><given-names>D</given-names></name>, <name><surname>Giger-Pabst</surname><given-names>U</given-names></name>, <name><surname>Reymond</surname><given-names>MA</given-names></name>. <article-title>Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis</article-title>. <source>Colorectal Dis</source>. <year>2016</year>
<month>4</month>;<volume>18</volume>(<issue>4</issue>):<fpage>364</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/codi.13130">10.1111/codi.13130</ext-link></comment>
<pub-id pub-id-type="pmid">26400556</pub-id></mixed-citation></ref><ref id="pone.0186709.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Nadiradze</surname><given-names>G</given-names></name>, <name><surname>Giger-Pabst</surname><given-names>U</given-names></name>, <name><surname>Zieren</surname><given-names>J</given-names></name>, <name><surname>Strumberg</surname><given-names>D</given-names></name>, <name><surname>Solass</surname><given-names>W</given-names></name>, <name><surname>Reymond</surname><given-names>MA</given-names></name>. <article-title>Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis</article-title>. <source>J Gastrointest Surg</source>. <year>2016</year>; <volume>20</volume>: <fpage>367</fpage>&#x02013;<lpage>373</lpage>. Published online 2015 Oct 28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11605-015-2995-9">10.1007/s11605-015-2995-9</ext-link></comment>
<pub-id pub-id-type="pmid">26511950</pub-id></mixed-citation></ref><ref id="pone.0186709.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>G&#x000f6;hler</surname><given-names>D</given-names></name>, <name><surname>Khosrawipour</surname><given-names>V</given-names></name>, <name><surname>Khosrawipour</surname><given-names>T</given-names></name>, <name><surname>Diaz-Carballo</surname><given-names>D</given-names></name>, <name><surname>Falkenstein</surname><given-names>TA</given-names></name>, <name><surname>Zieren</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Technical description of the microinjection pump (MIP) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC)</article-title>. <source>Surg Endosc</source>. <year>2017</year>
<month>4</month>;<volume>31</volume>(<issue>4</issue>):<fpage>1778</fpage>&#x02013;<lpage>1784</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00464-016-5174-5">10.1007/s00464-016-5174-5</ext-link>.</comment> Epub 2016 Sep 8 <pub-id pub-id-type="pmid">27631320</pub-id></mixed-citation></ref><ref id="pone.0186709.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Khosrawipour</surname><given-names>V</given-names></name>, <name><surname>Khosrawipour</surname><given-names>T</given-names></name>, <name><surname>Falkenstein</surname><given-names>TA</given-names></name>, <name><surname>Diaz-Carballo</surname><given-names>D</given-names></name>, <name><surname>F&#x000f6;rster</surname><given-names>E</given-names></name>, <name><surname>Osma</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Evaluating the Effect of Micropump Position, Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model</article-title>. <source>Anticancer Res</source>. <year>2016</year>
<month>9</month>;<volume>36</volume>(<issue>9</issue>):<fpage>4595</fpage>&#x02013;<lpage>600</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.21873/anticanres.11008">10.21873/anticanres.11008</ext-link></comment>
<pub-id pub-id-type="pmid">27630300</pub-id></mixed-citation></ref><ref id="pone.0186709.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Solass</surname><given-names>W</given-names></name>, <name><surname>Giger-Pabst</surname><given-names>U</given-names></name>, <name><surname>Zieren</surname><given-names>J</given-names></name>, <name><surname>Reymond</surname><given-names>MA</given-names></name>. <article-title>Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects</article-title>. <source>Ann Surg Oncol</source>. <year>2013</year>
<month>10</month>;<volume>20</volume>(<issue>11</issue>):<fpage>3504</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1245/s10434-013-3039-x">10.1245/s10434-013-3039-x</ext-link>.</comment> Epub 2013 Jun 14. <pub-id pub-id-type="pmid">23765417</pub-id></mixed-citation></ref><ref id="pone.0186709.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Le Scodan</surname><given-names>R</given-names></name>, <name><surname>Mornex</surname><given-names>F</given-names></name>, <name><surname>Partensky</surname><given-names>C</given-names></name>, <name><surname>Mercier</surname><given-names>C</given-names></name>, <name><surname>Valette</surname><given-names>PJ</given-names></name>, <name><surname>Ychou</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial</article-title>. <source>Am J Clin Oncol</source>. <year>2008</year>
<month>12</month>;<volume>31</volume>(<issue>6</issue>):<fpage>545</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/COC.0b013e318172d5c5">10.1097/COC.0b013e318172d5c5</ext-link></comment>
<pub-id pub-id-type="pmid">19060585</pub-id></mixed-citation></ref><ref id="pone.0186709.ref019"><label>19</label><mixed-citation publication-type="other">Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services. National Institutes of Health, National Cancer Institute</mixed-citation></ref><ref id="pone.0186709.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Prigerson</surname><given-names>HG</given-names></name>, <name><surname>Bao</surname><given-names>Y</given-names></name>, <name><surname>Shah</surname><given-names>MA</given-names></name>, <name><surname>Paulk</surname><given-names>ME</given-names></name>, <name><surname>LeBlanc</surname><given-names>TW</given-names></name>, <name><surname>Schneider</surname><given-names>BJ</given-names></name>, <etal>et al</etal>
<article-title>Chemotherapy Use, Performance Status, and Quality of Life at the End of Life</article-title>. <source>JAMA Oncol</source>. <year>2015</year>
<month>9</month>;<volume>1</volume>(<issue>6</issue>):<fpage>778</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamaoncol.2015.2378">10.1001/jamaoncol.2015.2378</ext-link></comment>
<pub-id pub-id-type="pmid">26203912</pub-id></mixed-citation></ref><ref id="pone.0186709.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>Ze</given-names></name>, <name><surname>Wang</surname><given-names>Jie</given-names></name>, <name><surname>Guillaume Wientjes</surname><given-names>M</given-names></name>, and <name><surname>Jessie</surname><given-names>L-S Au</given-names></name>. <article-title>Intraperitoneal therapy for peritoneal cancer</article-title>. <source>Future Oncol</source>. <year>2010</year>
<month>10</month>; <volume>6</volume>(<issue>10</issue>): <fpage>1625</fpage>&#x02013;<lpage>1641</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2217/fon.10.100">10.2217/fon.10.100</ext-link></comment>
<pub-id pub-id-type="pmid">21062160</pub-id></mixed-citation></ref><ref id="pone.0186709.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Takahara</surname><given-names>N</given-names></name>, <name><surname>Isayama</surname><given-names>H</given-names></name>, <name><surname>Nakai</surname><given-names>Y</given-names></name>, <name><surname>Ishigami</surname><given-names>H</given-names></name>, <name><surname>Satoi</surname><given-names>S</given-names></name>, <name><surname>Mizuno</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites</article-title>. <source>Invest New Drugs</source>. <year>2016</year>
<month>10</month>;<volume>34</volume>(<issue>5</issue>):<fpage>636</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10637-016-0369-0">10.1007/s10637-016-0369-0</ext-link>.</comment> Epub 2016 Jun <pub-id pub-id-type="pmid">27339809</pub-id></mixed-citation></ref><ref id="pone.0186709.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Grass</surname><given-names>F</given-names></name>, <name><surname>Vuagniaux</surname><given-names>A</given-names></name>, <name><surname>Teixeira-Farinha</surname><given-names>H</given-names></name>, <name><surname>Lehmann</surname><given-names>K</given-names></name>, <name><surname>Demartines</surname><given-names>N</given-names></name>, <name><surname>H&#x000fc;bner</surname><given-names>M</given-names></name>. <article-title>Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis</article-title>. <source>Br J Surg</source>. <year>2017</year>
<month>5</month>;<volume>104</volume>(<issue>6</issue>):<fpage>669</fpage>&#x02013;<lpage>678</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/bjs.10521">10.1002/bjs.10521</ext-link>.</comment> Review. <pub-id pub-id-type="pmid">28407227</pub-id></mixed-citation></ref><ref id="pone.0186709.ref024"><label>24</label><mixed-citation publication-type="other">M M&#x000fc;nch, R Kam, N Braun, J Latus, W Steurer, C Ulmer. Enkapsulierende peritoneale Sklerose nach intraoperativer intraperitonealer Chemotherapie. Ist das m&#x000f6;glich? Z Gastroenterol 2013; 51&#x02014;K362 10.1055/s-0033-1353012. German.</mixed-citation></ref><ref id="pone.0186709.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Graversen</surname><given-names>M</given-names></name>, <name><surname>Detlefsen</surname><given-names>S</given-names></name>, <name><surname>Bjerregaard</surname><given-names>JK</given-names></name>, <name><surname>Pfeiffer</surname><given-names>P</given-names></name>, <name><surname>Mortensen</surname><given-names>MB</given-names></name>. <article-title>Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)</article-title>. <source>Clin Exp Metastasis</source>. <year>2017</year>
<month>5</month>
<day>17</day>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10585-017-9849-7">10.1007/s10585-017-9849-7</ext-link>.</comment> [Epub ahead of print] <pub-id pub-id-type="pmid">28516306</pub-id></mixed-citation></ref><ref id="pone.0186709.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Solass</surname><given-names>W</given-names></name>, <name><surname>Sempoux</surname><given-names>C</given-names></name>, <name><surname>Detlefsen</surname><given-names>S</given-names></name>, <name><surname>Carr</surname><given-names>NJ</given-names></name>, <name><surname>Bibeau</surname><given-names>F</given-names></name>. <article-title>Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS)</article-title>. <source>Pleura and Peritoneum</source>. <year>2016</year>;<volume>1</volume>:<issue>99</issue>:<fpage>99</fpage>&#x02013;<lpage>107</lpage></mixed-citation></ref><ref id="pone.0186709.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Robella</surname><given-names>M</given-names></name>, <name><surname>Vaira</surname><given-names>M</given-names></name>, <name><surname>De Simone</surname><given-names>M</given-names></name>. <article-title>Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis</article-title>. <source>World J Surg Oncol</source>. <year>2016</year>
<month>4</month>
<day>29</day>;<volume>14</volume>:<fpage>128</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12957-016-0892-7">10.1186/s12957-016-0892-7</ext-link></comment>
<pub-id pub-id-type="pmid">27125996</pub-id></mixed-citation></ref></ref-list></back></article>